Skip to content

Talk Bio

Actionable Insights Powered by AI

Subscribe
  • Privacy policy
  • Subscribe
  • Home
  • Clinical Trials
  • Page 24

Clinical Trials

  • Biologically Active Substance
  • ENTITY
  • GPE

Syros Discontinues Mid-Stage Tamibarotene Program in Frontline Acute Myeloid Leukemia (AML)

11 months ago talkbio0Tagged Agonist, azacitidine, Clinical Trials, Futility Analysis, Leukemia, Myelocytic, Acute, RARα, SELECT-AML-1, Syros Pharmaceuticals, tamibarotene, venetoclax

Syros Pharmaceuticals, Tamibarotene, Acute Myeloid Leukemia (AML), Clinical Trial, SELECT-AML-1, Venetoclax, Azacitidine, RARα Agonist, Futility Analysis

Read More
  • Amino Acid, Peptide, or Protein
  • ENTITY
  • Geographic Area

Acelyrin Shifts Focus Amid Izokibep Setbacks, Lays Off Staff to Pursue Tepezza’s Market Share

11 months ago talkbio0Tagged Acelyrin, Clinical Trials, Izokibep, Market, setbacks, Strategy, Tepezza

Acelyrin, izokibep, clinical trial setbacks, layoffs, Tepezza, market strategy

Read More
  • ENTITY
  • Neoplastic Process
  • ORG

Halda Therapeutics Secures $126M to Advance ‘Hold and Kill’ Solid Tumor Drugs into Clinical Trials

11 months ago talkbio0Tagged Cancer Therapeutic Procedure, Clinical Trials, Halda, Malignant neoplasm of breast, Malignant neoplasm of prostate, RIPTAC, Series B extension financing, Solid Neoplasm

Halda Therapeutics, RIPTAC therapeutics, cancer treatment, solid tumors, prostate cancer, breast cancer, clinical trials, Series B extension financing

Read More
  • Disease or Syndrome
  • ENTITY
  • Pharmacologic Substance

Analysts Uncover Nuances in Avidity’s DMD Data, Highlighting Promising Results

11 months ago talkbio0Tagged Avidity, Biosciences, Clinical Trials, Duchenne, Muscular Dystrophy, Muscular Dystrophy, Duchenne, RNA therapy

Avidity Biosciences, DMD, Duchenne Muscular Dystrophy, RNA therapy, phase 1/2 data, clinical trials, biotech, pharmaceuticals

Read More
  • Amino Acid, Peptide, or Protein
  • ENTITY
  • GPE

Pfizer Strengthens Case for RSV Vaccine with Positive Data in Vulnerable Adults

11 months ago talkbio0Tagged Abrysvo, Clinical Trials, Immune response, immunocompromised adults, Pfizer, regulatory approval, Respiratory syncytial virus, Vaccines

Pfizer, RSV vaccine, Abrysvo, immunocompromised adults, clinical trial, immune responses, regulatory approval

Read More
  • Disease or Syndrome
  • ENTITY
  • Neoplastic Process

Halda Therapeutics Secures $126M in Series B Funding to Advance Next-Gen Oral TACs

11 months ago talkbio0Tagged Clinical Trials, Cluster headaches and other trigeminal autonomic cephalgias, Halda, Malignant neoplasm of prostate, next-gen, Series B

Halda Therapeutics, Series B funding, next-gen oral TACs, biotech, clinical trials, prostate cancer

Read More
  • Disease or Syndrome
  • ENTITY
  • Human-caused Phenomenon or Process

Autoimmune CAR-Ts Under Scrutiny Following Cabaletta’s Safety Concerns in Lupus Treatment

11 months ago talkbio0Tagged Autoimmune CAR-T, Cabaletta, Clinical Trials, concerns, Lupus Vulgaris, Safety

Autoimmune CAR-T, Cabaletta, Lupus, Safety Concerns, Clinical Trials

Read More
  • Amino Acid, Peptide, or Protein
  • Element, Ion, or Isotope
  • ENTITY

Actinium to Pursue Additional Clinical Trial for AML Radioactive Drug Following FDA Request

11 months ago talkbio0Tagged Actinium, Clinical Trials, Iomab-B, Leukemia, Myelocytic, Acute, radioactive drug, SIERRA, United States Food and Drug Administration

Actinium Pharmaceuticals, AML, radioactive drug, FDA, clinical trial, Iomab-B, SIERRA trial

Read More
  • Biologically Active Substance
  • ENTITY
  • Human-caused Phenomenon or Process

Nuvation Bio Halts Development of BET Inhibitor NUV-868 Following Interim Phase 1 Data Review

11 months ago talkbio0Tagged BD2-selective BET Inhibitor NUV-868, Bio, Clinical Trials, Effectiveness, Gambling, Inhibitor, Nuvation, oncology drug, Phase 1 (qualifier value), Safety

Nuvation Bio, BET inhibitor, NUV-868, Phase 1 data, oncology drug, safety and efficacy, clinical trials

Read More
  • Disease or Syndrome
  • ENTITY
  • LOC

Galapagos Halts BCMA CAR-T Study Due to Parkinsonism Case

11 months ago talkbio0Tagged bis(3-bis(4-chlorophenyl)methyl-4-dimethylaminophenyl)amine, CAR-T, Clinical Trials, Galapagos, GLPG5301, Multiple Myeloma, PAPILIO-1, Parkinsonian Disorders

Galapagos, BCMA CAR-T, Parkinsonism, multiple myeloma, CAR-T therapy, clinical trial, PAPILIO-1 study, GLPG5301

Read More

Posts pagination

Previous 1 … 23 24 25 … 34 Next

Organizations

Agencies amgen AstraZeneca boehringer ingelheim Centers for Disease Control and Prevention (U.S.) Congress (U.S. Legislature) court Drug Industry European Medicines Agency genentech Government Health care facility Johnson and Johnson Moderna Novavax Partnership Pfizer Pharmacy Benefit Manager Pharmacy facility Roche (company) sandoz sanofi squibb United States Federal Trade Commission United States Food and Drug Administration World Health Organization

Concepts & Ideas

Accelerated Accelerated Approval Access accessibility Approved aspects of adverse effects asset Bankruptcy Benefit Capacity Capital Changing Chinese Language Clearance Clinical Data Combined commercial Complete Compound Contract agreement Cost Effectiveness development aspects Discontinuation (procedure) Diversity Dosage drug price Drug Shortage earnings Economic Inflation Effectiveness Efficiency Expectations Failed Failure (biologic function) Financial cost Financial savings financing characteristics Funding Generalized Health Identifier Improvement Increased Infrequent Legal Legal patent Long-term Moderate (severity modifier) New Drug Application Overall Survival Paroxysmal perioperative Phase 2 Phase 3 Prices Pricing Programs - Publication Format Progression-Free Survival Projections and Predictions Recommendation regulatory Review [Publication Type] rights Risk Series Statistical Significance Study on Hold subcutaneous Submission Symptoms aspect Toxicity aspects trends qualifier Variant Weekly

Procedures

Advice Cancer Therapeutic Procedure Cell Therapy Clinical Research Clinical Trials Combined Modality Therapy Confirmatory Trial Detection Drug Discovery Evaluation Gene Modification gene therapy HIV prevention Immunotherapy Injection of therapeutic agent Medical Research activity patient safety Pharmaceutical Services Pharmacotherapy Phase 2 Clinical Trials Phase 3 Clinical Trials Precision Medicine Prescription procedure Reparative closure research Telemedicine Vaccination

Occupations

Artificial Intelligence biology (field) Biotechnology Drug Development Genetic Medicine Global Health Immunology medical technology Neurology speciality Neuroscience discipline public health medicine (field) Science Science of genetics Technology

Disorders

Achondroplasia Acute onset pain Adverse event Amyotrophic Lateral Sclerosis Angioedemas, Hereditary Aortic Valve Insufficiency Asthma Attention deficit hyperactivity disorder Autoimmune Diseases Brain Neoplasms Burning Mouth Syndrome Cardiomyopathies Cardiovascular Diseases Chronic Kidney Diseases Chronic Obstructive Airway Disease Colorectal Carcinoma COVID19 (disease) Dental Plaque Dermatitis, Atopic Diabetes Diabetes Mellitus, Non-Insulin-Dependent Disease Progression Eczema Epilepsy Esophageal Neoplasms Fibrosis Heart failure Hematologic Neoplasms Hemophilia A Hemophilia B Hereditary Diseases Hypoparathyroidism IGA Glomerulonephritis Infantile Severe Myoclonic Epilepsy Inflammation Inflammatory Bowel Diseases Inflammatory disorder Kidney Diseases leukemia Liver and Intrahepatic Biliary Tract Carcinoma Liver diseases Lung diseases Lupus Nephritis Lymphoma, Follicular Malignant neoplasm of breast Malignant neoplasm of endometrium Malignant neoplasm of lung Malignant neoplasm of prostate Malignant neoplasm of stomach Malignant neoplasm of urinary bladder Malignant Neoplasms Malignant tumor of cervix melanoma Mental Depression Mental deterioration Metabolic Diseases Multiple Acyl Coenzyme A Dehydrogenase Deficiency Multiple Myeloma Multiple Sclerosis Muscular Dystrophy Muscular Dystrophy, Duchenne Nance-Horan syndrome Narcolepsy Neoplasms Nerve Degeneration nervous system disorder Neurodegenerative Disorders Non-Small Cell Lung Carcinoma Nonalcoholic Steatohepatitis Obesity Paroxysmal nocturnal hemoglobinuria Post-Traumatic Stress Disorder Primary Biliary Cholangitis Psoriasis Pulmonary arterial hypertension Pulmonary Hypertension Reduced Schizophrenia Seizures Severe (severity modifier) Small cell carcinoma of lung Solid Neoplasm Spinal Muscular Atrophy Ulcerative Colitis Urinary tract infection Weight Loss

Objects

Arrowhead Facility (object) Investments Labels (device)

Chemicals & Drugs

Agonist agonists Antibiotics Antibodies Antibodies, Bispecific Antibody-Drug Conjugates Antineoplastic Agents Biological Factors Biosimilars BTK Inhibitor Cancer Vaccines Caplyta Clesrovimab Clustered Regularly Interspaced Short Palindromic Repeats Donanemab Dosage Forms Dupixent durvalumab Enhertu Epidermal Growth Factor Receptor Glucagon-Like Peptide-1 Receptor Glucagon-Like Peptide 1 Humira Imfinzi Immunologic Adjuvants Immunostimulating conjugate (antigen) Inhibitor inhibitors Insulin Jemperli Keytruda Lenacapavir Lumateperone Microbicides Midomafetamine Monoclonal Antibodies Mounjaro Nitroglycerin/Sodium Citrate/Ethanol Solution obinutuzumab Ocaliva Opdivo Ozempic patritumab Pediatric brand name pembrolizumab Primary Endpoint Radiopharmaceuticals RNA RNA, Messenger RNA, Small Interfering Rybrevant semaglutide Stelara Tagrisso Tecentriq therapeutic autologous dendritic cells tirzepatide Tremfya Trodelvy Vaccines Wegovy Weight-Loss Agents Zantac

Activities & Behaviors

Acquisition (action) Administration occupational activities Advisory Committees Agreement authorization Automation business career CEO Collaboration competition Continuance of life Drug Approval Industry Leadership Machine Learning Manufacture Mediation Medicare National Security Optimization production Rating (action) Rejection (Psychology) Relations Sales - occupational activity Settlement and Resettlement Success Withdraw (activity)

Geographic Areas

California China Japan Market North Carolina Singapore United States

Phenomena

Emergency Situation Motor function (observable entity) Safety

Living Beings

Adult Child Consumer European (ethnic group) HIV Ira (eukaryote) manager Partner in relationship Pet Animal Plants Plant seeds Respiratory syncytial virus

Anatomy

Cardiovascular system Carvykti Cells Liver Neurosecretory Systems T-Lymphocyte

Physiology

Biological Markers cellular targeting Cessation of life Decision Gene Expression Growth Hearing Immune response Menopause mental health Mutation Practice Experience Response process RNA Interference

Genes & Molecular Sequences

CSHL1 gene K-ras Oncogene PDCD1 gene PREP gene TIGIT gene TYK2 gene
Copyright © TalkBio 2024 Proudly powered by WordPress | Theme: ogma-blog by Mystery Themes.
  • Privacy policy
  • Subscribe